AI Engines For more Details: Perplexity Kagi Labs You
Antiretroviral Therapy (ART): Didanosine is a key component of combination antiretroviral therapy (ART) regimens used in the management of HIV infection. When used in combination with other antiretroviral medications, such as protease inhibitors or non-nucleoside reverse transcriptase inhibitors, didanosine helps suppress viral replication, reduce HIV-related symptoms, and improve immune function.
Viral Load Suppression: By inhibiting the replication of HIV, didanosine helps reduce the amount of virus (viral load) in the blood and other bodily fluids, thereby slowing the progression of HIV infection and delaying the onset of AIDS (acquired immunodeficiency syndrome).
CD4 Cell Count Elevation: Didanosine therapy is associated with increases in CD4 T-cell counts, which are a key indicator of immune function in individuals with HIV infection. By restoring and preserving CD4 cell counts, didanosine helps strengthen the immune system and reduce the risk of opportunistic infections and AIDS-related complications.
Prevention of Vertical Transmission: Didanosine, when used as part of combination ART during pregnancy and childbirth, has been shown to significantly reduce the risk of vertical transmission of HIV from mother to child. Effective management of HIV during pregnancy with ART can greatly reduce the risk of mother-to-child transmission and improve outcomes for both the mother and the baby.
Adverse Effects: While didanosine is generally well-tolerated, it can cause adverse effects, particularly gastrointestinal side effects such as nausea, vomiting, diarrhea, and abdominal pain. Other potential side effects may include pancreatitis, hepatotoxicity (liver damage), peripheral neuropathy, rash, and metabolic abnormalities. It's important for individuals taking didanosine to report any new or worsening symptoms to their healthcare provider promptly.
Drug Interactions: Didanosine may interact with other medications, including antacids containing aluminum or magnesium, which can reduce its absorption and effectiveness. It's essential for individuals taking didanosine to inform their healthcare provider about all other medications, supplements, and over-the-counter drugs they are using to avoid potential interactions.
Resistance: Like other antiretroviral medications, the development of drug resistance is a concern with didanosine therapy. To minimize the risk of resistance, didanosine should be used in combination with other antiretroviral drugs as part of a comprehensive ART regimen, and adherence to the prescribed treatment regimen is crucial.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
| ADHD | 0.2 | 0.2 | |
| Age-Related Macular Degeneration and Glaucoma | 0.2 | -0.2 | |
| Allergic Rhinitis (Hay Fever) | 0.6 | 0.6 | |
| Allergies | 0 | 0 | |
| Allergy to milk products | 0 | 0.3 | 0 |
| Alopecia (Hair Loss) | 0.5 | 0.5 | |
| Alzheimer's disease | 0.3 | 0.6 | -1 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0 | 0 | 0 |
| Ankylosing spondylitis | 0.6 | 0.3 | 1 |
| Anorexia Nervosa | 0.2 | 0.2 | |
| Antiphospholipid syndrome (APS) | 0.1 | 0.2 | -1 |
| Atrial fibrillation | 0.3 | 0.5 | -0.67 |
| Autism | 0.7 | 0.6 | 0.17 |
| Barrett esophagus cancer | 0.1 | -0.1 | |
| benign prostatic hyperplasia | 0 | 0 | |
| Bipolar Disorder | 0.5 | 0.5 | |
| Carcinoma | 0.6 | 0.2 | 2 |
| Celiac Disease | 0.1 | 0.5 | -4 |
| Cerebral Palsy | 0.1 | 0.1 | |
| Chronic Fatigue Syndrome | 0.9 | 0.5 | 0.8 |
| Chronic Kidney Disease | 0.7 | 0.7 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | 0.2 | |
| Chronic Urticaria (Hives) | 0.1 | 0.1 | |
| Coagulation / Micro clot triggering bacteria | 0.4 | 0.1 | 3 |
| Colorectal Cancer | 0.3 | 0.3 | |
| Constipation | 0 | 0 | |
| Coronary artery disease | 0.3 | 0.3 | |
| COVID-19 | 1.2 | 0.9 | 0.33 |
| Crohn's Disease | 0.9 | 0.2 | 3.5 |
| cystic fibrosis | 0.1 | 0.1 | |
| deep vein thrombosis | 0.1 | 0.1 | 0 |
| Depression | 2.1 | 1.1 | 0.91 |
| Dermatomyositis | 0.1 | 0.1 | |
| Eczema | 0.3 | 0.1 | 2 |
| Endometriosis | 0.4 | 0.4 | |
| Epilepsy | 0.1 | 0.2 | -1 |
| Fibromyalgia | 1.1 | 1.1 | |
| Functional constipation / chronic idiopathic constipation | 0.3 | 0.1 | 2 |
| gallstone disease (gsd) | 0.3 | 0.3 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | -0.1 | |
| Generalized anxiety disorder | 0.4 | 0.4 | |
| Glioblastoma | 0.1 | -0.1 | |
| Graves' disease | 0.2 | 0.2 | |
| Halitosis | 0.1 | -0.1 | |
| Hashimoto's thyroiditis | 0.1 | 0.2 | -1 |
| Hidradenitis Suppurativa | 0.3 | 0.3 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0 | 0.1 | 0 |
| hyperglycemia | 0 | 0.2 | 0 |
| hypersomnia | 0.2 | -0.2 | |
| hypertension (High Blood Pressure | 0.3 | 0.3 | 0 |
| Hypoxia | 0.2 | 0.2 | |
| IgA nephropathy (IgAN) | 0.3 | -0.3 | |
| Inflammatory Bowel Disease | 1.3 | 0.5 | 1.6 |
| Insomnia | 0.1 | 0.1 | |
| Intracranial aneurysms | 0.2 | 0.2 | |
| Irritable Bowel Syndrome | 0.1 | 0.2 | -1 |
| Liver Cirrhosis | 0.6 | 0.3 | 1 |
| Long COVID | 1.5 | 0.5 | 2 |
| Lung Cancer | 0 | 0 | |
| ME/CFS with IBS | 0.1 | 0.1 | |
| ME/CFS without IBS | 0.5 | 0.5 | 0 |
| Metabolic Syndrome | 0.9 | 0.5 | 0.8 |
| Mood Disorders | 2.3 | 1.1 | 1.09 |
| multiple chemical sensitivity [MCS] | 0.1 | 0.1 | |
| Multiple Sclerosis | 0.6 | 0.8 | -0.33 |
| Multiple system atrophy (MSA) | 0.1 | 0.1 | |
| Neuropathy (all types) | 0.1 | 0 | 0 |
| neuropsychiatric disorders (PANDAS, PANS) | 0 | 0 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.1 | 0.1 | |
| Obesity | 1 | 1.1 | -0.1 |
| obsessive-compulsive disorder | 0.4 | 0.4 | 0 |
| Osteoarthritis | 1.2 | 1.2 | |
| Osteoporosis | 0 | 0 | |
| pancreatic cancer | 0.1 | 0.1 | |
| Parkinson's Disease | 0.6 | 0.1 | 5 |
| Polycystic ovary syndrome | 0.3 | 0.3 | |
| Premenstrual dysphoric disorder | 0.2 | -0.2 | |
| Psoriasis | 0.1 | 0.7 | -6 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.9 | 0.9 | |
| Rosacea | 0.1 | 0.1 | |
| Schizophrenia | 0.5 | 0.5 | |
| scoliosis | 0.2 | -0.2 | |
| Sjögren syndrome | 0.3 | 0.2 | 0.5 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | 0.1 | |
| Stress / posttraumatic stress disorder | 0.3 | 0.3 | |
| Systemic Lupus Erythematosus | 0.9 | 0.9 | |
| Type 1 Diabetes | 0.3 | 0.1 | 2 |
| Type 2 Diabetes | 0.9 | 0.3 | 2 |
| Ulcerative colitis | 0.5 | 0.5 | 0 |
| Unhealthy Ageing | 0.7 | 0.7 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.